Pharmaceutical Research

, 35:111 | Cite as

Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages

  • Matshawandile Tukulula
  • Luis Gouveia
  • Paulo Paixao
  • Rose Hayeshi
  • Brendon Naicker
  • Admire Dube
Research Paper



Mycobacterium tuberculosis which causes tuberculosis, is primarily resident within macrophages. 1,3-β-glucan has been proposed as a ligand to target drug loaded nanoparticles (NPs) to macrophages. In this study we characterized the intracellular pharmacokinetics of the anti-tubercular drug rifampicin delivered by 1,3-β-glucan functionalized PLGA NPs (Glu-PLGA). We hypothesized that Glu-PLGA NPs would be taken up at a faster rate than PLGA NPs, and consequently deliver higher amounts of rifampicin into the macrophages.


Carbodiimide chemistry was employed to conjugate 1,3-β-glucan and rhodamine to PLGA. Rifampicin loaded PLGA and Glu-PLGA NPs as well as rhodamine functionalized PLGA and Glu-PLGA NPs were synthesized using an emulsion solvent evaporation technique. Intracellular pharmacokinetics of rifampicin and NPs were evaluated in THP-1 derived macrophages. A pharmacokinetic model was developed to describe uptake, and modelling was performed using ADAPT 5 software.


The NPs increased the rate of uptake of rifampicin by a factor of 17 and 62 in case of PLGA and Glu-PLGA, respectively. Expulsion of NPs from the macrophages was also observed, which was 3 fold greater for Glu-PLGA NPs than for PLGA NPs. However, the ratio of uptake to expulsion was similar for both NPs. After 24 h, the amount of rifampicin delivered by the PLGA and Glu-PLGA NPs was similar. The NPs resulted in at least a 10-fold increase in the uptake of rifampicin.


Functionalization of PLGA NPs with 1,3-β-glucan resulted in faster uptake of rifampicin into macrophages. These NPs may be useful to achieve rapid intracellular eradication of Mycobacterium tuberculosis.

Key words

1,3-β-glucan nanoparticle drug delivery pharmacokinetic modelling PLGA nanoparticles rifampicin intracellular concentrations 







1-Ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochloride


Liquid chromatography mass spectrometry


Mycobacterium tuberculosis




Nuclear magnetic resonance spectroscopy






Phorbol myristate acetate






Acknowledgments and Disclosures

Author AD wishes to acknowledge financial support from the Council for Scientific and Industrial Research (CSIR) South Africa (YREF 2013 011) and the University of the Western Cape. This work is based on research supported in part by the National Research Foundation of South Africa (Grant Number 109059) awarded to AD.


  1. 1.
    WHO. Global tuberculosis report 2016. 19 November 2016. Available from:
  2. 2.
    Kusner DJ. Mechanisms of mycobacterial persistence in tuberculosis. Clin Immunol (Orlando, Fla). 2005;114(3):239–47.CrossRefGoogle Scholar
  3. 3.
    Verma RK, Kaur J, Kumar K, Yadav AB, Misra A. Intracellular time course, pharmacokinetics, and Biodistribution of isoniazid and Rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother. 2008;52(9):3195–201.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Xie S, Tao Y, Pan Y, Qu W, Cheng G, Huang L, et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J Control Release. 2014;187:101–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target. 2006;14(8):546–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Dube A, Reynolds JL, Law W-C, Maponga CC, Prasad PN, Morse GD. Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases. Nanomedicine. 2014;10(4):831–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sundaramurthi JC, Hanna LE, Selvaraju S, Brindha S, Joel Gnanadoss J, Vincent S, et al. TBDRUGS – database of drugs for tuberculosis. Tuberculosis. 2016;100:69–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Dube A, Lemmer Y, Hayeshi R, Balogun M, Labuschagne P, Swai H, et al. State of the art and future directions in nanomedicine for tuberculosis. Expert Opinion on Drug Delivery. 2013;10(12):1725–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Chono S, Tanino T, Seki T, Morimoto K. Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol. 2007;59(1):75–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release. 2008;127(1):50–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Tukulula M, Hayeshi R, Fonteh P, Meyer D, Ndamase A, Madziva MT, et al. Curdlan-conjugated PLGA nanoparticles possess macrophage stimulant activity and drug delivery capabilities. Pharm Res. 2015;32(8):2713–26.PubMedGoogle Scholar
  13. 13.
    Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, et al. Dectin-1 is a major β-glucan receptor on macrophages. J Exp Med. 2002;196(3):407–12.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Goodridge HS, Wolf AJ, Underhill DM. β-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2:25.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Adamczyk M, Grote J. Efficient synthesis of rhodamine conjugates through the 2′-position. Bioorg Med Chem Lett. 2000;10(14):1539–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Li M, Czyszczon EA, Reineke JJ. Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles. Drug Deliv Trans Res. 2013;3(6):551–61.CrossRefGoogle Scholar
  18. 18.
    Jiang L, He L, Fountoulakis M. Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J Chromatogr A. 2004;1023(2):317–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Ece Gamsiz D, Shah LK, Devalapally H, Amiji MM, Carrier RL. A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells. Biotechnol Bioeng. 2008;101(5):1072–82.CrossRefPubMedGoogle Scholar
  20. 20.
    D’Argenio D, Schumitzky A, Wang XADAPT. 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. USA: Biomedical Simulations Resource, CA; 2009.Google Scholar
  21. 21.
    Ramos SS, Vilhena AF, Santos L, Almeida P. 1H and 13C NMR spectra of commercial rhodamine ester derivatives. Magn Reson Chem. 2000;38(6):475–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of ChemistryTshwane University of TechnologyPretoriaSouth Africa
  2. 2.Research Institute for Medicines (iMed.ULisboa), Faculty of PharmacyUniversidade de Lisboa,LisbonPortugal
  3. 3.DST/NWU Preclinical Drug Development PlatformNorth-West University,PotchefstroomSouth Africa
  4. 4.Council for Scientific and Industrial ResearchPolymers and CompositesPretoriaSouth Africa
  5. 5.Discipline of Pharmaceutics, School of PharmacyUniversity of the Western Cape,BellvilleSouth Africa

Personalised recommendations